CWY

SciSparc and Clearmind Collaboration Continues to Increase its Patent Portfolio in the Field of Movement Abnormalities in the U.S.

Retrieved on: 
화요일, 8월 1, 2023
Patent, Extremities, CSE, Central nervous system, Therapy, Tic disorder, Face, United States Patent and Trademark Office, DSM-IV codes, Tourette syndrome, Dystonia, FSE, IP, TEL, Disorder, Parkinson's disease, CWY, Chorea, Pharmaceutical industry, Dyskinesia

The provisional patent application was filed with the United States Patent and Trademark Office.

Key Points: 
  • The provisional patent application was filed with the United States Patent and Trademark Office.
  • This patent application refers to combination of the psychedelic molecule 3-Methylmethcathinone, known as 3-MMC, and SciSparc's Palmitoylethanolamide as a potential treatment for dyskinesia.
  • This patent prospect corresponds well with SciSparc’s robust IP portfolio and some of the indications the Company is already pursuing such as Tourette Syndrome.
  • Our collaboration with Clearmind continues to bear fruit and emphasizes our commitment to pioneering innovative treatments for conditions with unmet need,” stated SciSparc’s Chief Executive Officer, Oz Adler.

Clearmind Medicine Files Patent Application with USPTO for the Treatment of Dyskinesia; Further Strengthens its Already Robust IP Portfolio

Retrieved on: 
화요일, 8월 1, 2023
Patent, Extremities, CSE, Obesity, Therapy, Face, United States Patent and Trademark Office, DSM-IV codes, MEAI, Dystonia, FSE, Disorder, Parkinson's disease, Patient, CWY, Myenteric plexus, Chorea, Pharmaceutical industry, Dyskinesia

The patent application refers to the psychedelic molecule 3-Methylmethcathinone ("3-MMC”) as a potential treatment for Dyskinesia thus expanding Clearmind’s IP portfolio for innovative molecules, new indications and treatments.

Key Points: 
  • The patent application refers to the psychedelic molecule 3-Methylmethcathinone ("3-MMC”) as a potential treatment for Dyskinesia thus expanding Clearmind’s IP portfolio for innovative molecules, new indications and treatments.
  • "Clearmind continues to strengthen its position as a leader in the psychedelic-derived therapeutics industry through an aggressive strategy to expand our IP portfolio.
  • Clearmind has a broad IP footprint in the psychedelic space with 30 patents and patent applications across 14 patent families, nine of which have been granted in major jurisdictions like the US, Europe, China, and India.
  • The company has already filed patent applications for the combination of Clearmind's MEAI with SciSparc's Palmitoylethanolamide for treating alcohol use disorder, cocaine addiction, and obesity, as well as related metabolic disorders.

Clearmind Medicine Announces Share-Based Payment for the Company's Consultants

Retrieved on: 
월요일, 7월 17, 2023
CSE, FSE, Therapy, CWY, Consultant, Pharmaceutical industry

Tel Aviv, Israel / Vancouver, Canada, July 17, 2023 (GLOBE NEWSWIRE) --  Clearmind Medicine Inc. (Nasdaq, CSE: CMND), (FSE: CWY) (“Clearmind” or the "company"), a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, today announced that it has issued 17,899 common shares in the capital of the Company ("Shares") in lieu of the final payment of $10,000, starting May 1st 2022, to consultants of the Company.

Key Points: 
  • Tel Aviv, Israel / Vancouver, Canada, July 17, 2023 (GLOBE NEWSWIRE) --  Clearmind Medicine Inc. (Nasdaq, CSE: CMND), (FSE: CWY) (“Clearmind” or the "company"), a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, today announced that it has issued 17,899 common shares in the capital of the Company ("Shares") in lieu of the final payment of $10,000, starting May 1st 2022, to consultants of the Company.
  • In addition, the Company has issued restricted stock units ("RSUS") for additional consultant in lieu of payment of $5,000.
  • All Shares will only be subjected to those restrictions designated in applicable securities laws.

Dr. Fatima Cody Stanford, Associate Professor of Medicine and Pediatrics at Harvard Medical School, Joins Clearmind Medicine's Scientific Advisory Board

Retrieved on: 
화요일, 7월 11, 2023
Emory University, Obesity, CSE, Harvard Kennedy School, Pediatrics, Hebrew University of Jerusalem, Therapy, Obesity medicine, Public, Medical college, Policy, Weight loss, MEAI, Al-Quds, Business, Master of Public Administration, Coronavirus Scientific Advisory Board, FSE, Quantic School of Business and Technology, Associate, Harvard Medical School, Public health, Animal, MD, Metabolic syndrome, CWY, Motivation, Liver, Hospital, Massachusetts General Hospital, Master, Pharmaceutical industry, Management, Science, Medicine

Dr. Stanford is currently associated with Massachusetts General Hospital and is an Associate Professor of Medicine and Pediatrics at Harvard Medical School, where she serves as an educator, researcher, and policy maker.

Key Points: 
  • Dr. Stanford is currently associated with Massachusetts General Hospital and is an Associate Professor of Medicine and Pediatrics at Harvard Medical School, where she serves as an educator, researcher, and policy maker.
  • Dr. Stanford completed her Obesity Medicine & Nutrition Fellowship at Massachusetts General Hospital and Harvard Medical School, further enhancing her expertise in the field.
  • With a career dedicated to bridging the gaps between medicine, public health, and policy, Dr. Stanford has become a sought-after expert in obesity medicine, both nationally and internationally.
  • "We are delighted to welcome Dr. Fatima Cody Stanford to our Scientific Advisory Board.

Clearmind Medicine and SciSparc to Conduct Study Evaluating Combination Treatment for Obesity and Metabolic Syndrome

Retrieved on: 
금요일, 6월 16, 2023
Obesity, CSE, Central nervous system, Depression, Hebrew University of Jerusalem, Therapy, Metabolism, Weight loss, MEAI, Al-Quds, FSE, Research, Cannabinoid, Human, PEA, Animal, Patent, Metabolic syndrome, CWY, Motivation, Liver, Cocaine, Pharmaceutical industry, Dietary supplement, Yissum Research Development Company of the Hebrew University

Tel Aviv, Israel / Vancouver, Canada, June 16, 2023 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq, CSE: CMND), (FSE: CWY) (“Clearmind” or the "company"), a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, today announced that as part of the Company's ongoing collaboration with SciSparc Ltd. (NASDAQ: SPRC) ("SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, it has entered into a research agreement with the Hebrew University of Jerusalem, to evaluate Clearmind's and SciSparc's combination treatment for obesity and metabolic syndrome.

Key Points: 
  • "We are excited to further investigate the effect of the combination of MEAI and PEA for treating obesity and metabolic syndrome.
  • Previous pre-clinical studies performed with our proprietary MEAI showed a very positive effect in treating obesity.
  • "The collaboration with SciSparc has already yielded numerous patent applications related to combination therapies for treating binge behaviors, cocaine addiction, depression and more."
  • The upcoming study will evaluate the effect of the combination of MEAI and PEA on food intake, metabolic and activity profiles.

Clearmind Medicine to Host Virtual Investor Conference on Psychedelics for Obesity

Retrieved on: 
금요일, 6월 9, 2023
Business development, Obesity, CSE, Therapy, Metabolism, Drug development, MEAI, FSE, Associate, Hebrew language, Metabolic syndrome, CWY, Pharmaceutical industry, Pharmacology

Tel Aviv, Israel / Vancouver, Canada, June 09, 2023 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (NASDAQ: CMND) (CSE: CMND), (FSE: CWY) (“Clearmind” or “the Company"), a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, will host a virtual investor conference titled “Psychedelics for Obesity” on Monday, June 12th, at 10:00 AM EST.

Key Points: 
  • The conference will stream live on Monday, June 12, at 10:00 AM EST
    Tel Aviv, Israel / Vancouver, Canada, June 09, 2023 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (NASDAQ: CMND) (CSE: CMND), (FSE: CWY) (“Clearmind” or “the Company"), a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, will host a virtual investor conference titled “Psychedelics for Obesity” on Monday, June 12th, at 10:00 AM EST.
  • Clearmind recently announced positive pre-clinical results demonstrating efficacy of its drug candidate MEAI for treating obesity and metabolic syndrome.
  • Professor Tam will headline the conference discussing the challenges of obesity and the promising pre-clinical results for MEAI as a potential treatment.
  • The conference will also feature Mark Haden, Clearmind's VP of Business Development, and will be hosted by Shannon Smadella of Clearmind’s Community Development department.

Clearmind Medicine Announces First US Site for its Phase I/IIa Clinical Trial Evaluating CMND-100 in Patients with Alcohol Use Disorder

Retrieved on: 
월요일, 5월 22, 2023
Mount Sinai Beth Israel, Medical school, CSE, Therapy, Yale School of Medicine, Clinical trial, MEAI, FSE, Research, Yale school, Mount Sinai, IP, Assistant, Ethics committee, AUD, Crave, MD, Patient, CWY, FIH, Phase, Safety, Substance abuse, Pharmaceutical industry, Psychiatry, Medicine

Yale School of Medicine’s Department of Psychiatry is the first US-based clinical site to join the company's first-in-human (FIH) trial.

Key Points: 
  • Yale School of Medicine’s Department of Psychiatry is the first US-based clinical site to join the company's first-in-human (FIH) trial.
  • The site will be led by Anahita Bassir Nia, MD, a specialist in substance abuse, including alcohol abuse.
  • The CM-CMND-001 clinical trial is a multinational, multi-center, Phase I/II single- and multiple-dose tolerability, safety and pharmacokinetic study in healthy volunteers and AUD subjects.
  • The patients will report their drinking patterns and craving for alcohol (and cigarettes) during the clinical trial period.

Clearmind Medicine Announces Receipt of Nasdaq Minimum Bid Price Notification

Retrieved on: 
금요일, 5월 19, 2023
CSE, Therapy, Calendar, FSE, Notice, CWY, Auction

Tel Aviv, Israel / Vancouver, Canada, May 19, 2023 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (NASDAQ: CMND) (CSE: CMND), (FSE: CWY) (“Clearmind” or “the Company"), a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, today announced that it has received a written notice (the "Notice") from the Nasdaq Stock Market LLC ("Nasdaq") indicating that the Company is not in compliance with the minimum bid price requirement for continued listing set forth in Nasdaq Listing Rule 5550(a)(2), which requires listed securities to maintain a minimum bid price of $1.00 per share.

Key Points: 
  • Tel Aviv, Israel / Vancouver, Canada, May 19, 2023 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (NASDAQ: CMND) (CSE: CMND), (FSE: CWY) (“Clearmind” or “the Company"), a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, today announced that it has received a written notice (the "Notice") from the Nasdaq Stock Market LLC ("Nasdaq") indicating that the Company is not in compliance with the minimum bid price requirement for continued listing set forth in Nasdaq Listing Rule 5550(a)(2), which requires listed securities to maintain a minimum bid price of $1.00 per share.
  • Under Nasdaq Listing Rule 5810(c)(3)(A), the Company has been granted a grace period of 180 calendar days to regain compliance with the minimum bid price requirement.
  • The Notice does not immediately affect the Company's Nasdaq listing or the trading of its ordinary shares.
  • According to the Notice, the Company has until November 13, 2023, to regain compliance with the minimum bid price requirement.

Clearmind Medicine to Host Virtual Investor Conference on Psychedelics for Obesity

Retrieved on: 
수요일, 5월 17, 2023
Business development, Obesity, CSE, Therapy, Metabolism, Drug development, MEAI, FSE, Associate, Hebrew language, Metabolic syndrome, CWY, Pharmaceutical industry, Pharmacology

Tel Aviv, Israel / Vancouver, Canada, May 17, 2023 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (NASDAQ: CMND) (CSE: CMND), (FSE: CWY) (“Clearmind” or “the Company"), a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, will host a virtual investor conference titled “Psychedelics for Obesity” on Monday, June 12th, at 10:00 AM EST.

Key Points: 
  • The conference will stream live on Monday, June 12, at 10:00 AM EST
    Tel Aviv, Israel / Vancouver, Canada, May 17, 2023 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (NASDAQ: CMND) (CSE: CMND), (FSE: CWY) (“Clearmind” or “the Company"), a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, will host a virtual investor conference titled “Psychedelics for Obesity” on Monday, June 12th, at 10:00 AM EST.
  • Clearmind recently announced positive pre-clinical results demonstrating efficacy of its drug candidate MEAI for treating obesity and metabolic syndrome.
  • Professor Tam will headline the conference discussing the challenges of obesity and the promising pre-clinical results for MEAI as a potential treatment.
  • The conference will also feature Mark Haden, Clearmind's VP of Business Development, and will be hosted by Shannon Smadella of Clearmind’s Community Development department.

Clearmind Medicine Announces IRB Approval to Conduct Clinical Trial on Alcohol Use Disorder

Retrieved on: 
금요일, 5월 12, 2023
Institutional review board, Human, Sheba Medical Center, CSE, Therapy, Clinical trial, MEAI, FSE, Research, IMCA, Privacy, USD, Ethics committee, Committee, AUD, Crave, Ethics, Patient, IRB, CWY, Death, Safety, Pharmaceutical industry

Tel Aviv, Israel / Vancouver, Canada, May 12, 2023 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq, CSE: CMND), (FSE: CWY) (“Clearmind” or the "company"), a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, has received Ethics Committee approval for its CM-CMND-001 Phase I/II clinical trial of its MEAI-based CMND-100 compound for the treatment of alcohol use disorder ("AUD") at Israel’s IMCA center.

Key Points: 
  • CM-CMND-001 is a multinational, multi-center, single and multiple dose tolerability, safety and pharmacokinetic Study of CMND-100 in healthy volunteers and AUD subjects.
  • The company intends to have two additional sites in the United States, for this study, subject to signing an agreement with local sites.
  • The patients will report their drinking patterns and craving for alcohol (and cigarettes) during the clinical trial period.
  • “Ethics Committee approval of the study marks a key step forward in beginning the first-in-human clinical trial of CMND-100," said Clearmind’s Chief Executive Officer, Dr. Adi Zuloff-Shani.